Subscribe To

Price Alert Latest News Economic Calendar News

LMLLF / PharmaDrug submits US provisional patent application for cepharanthine to treat prostate cancer

PharmaDrug Inc announced that it has filed a US provisional patent application which details the novel synergistic combination of cepharanthine (PD-001) ) and cabazitaxel on prostate cancer growth inhibition. The company said that it also set forth claims related to the use of PD-001, cabazitaxel and/or other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancer. Read More

Demo Live Account See Partner Details

Content Topics

Bmo

Women

In

Leadership

Fund

Womn

To

Pharmadrug

Submits

Provisional

Patent

Application

Cepharanthine

Prostate

Cancer

Stock

LMLLF

Posted: Feb 1 2022, 10:03

Author Name: Proactive Investors

LMLLF News

By Proactive Investors
October 27, 2023

PharmaDrug to acquire Securedose Synthetics in all-stock deal

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced that it will acquire all of the issued and outstanding shares of Securedose Synthetics Inc, a privat

By Proactive Investors
October 23, 2023

PharmaDrug to consolidate shares, appoints new CFO

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) (PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF), PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF)). said it will consolidate its

By Proactive Investors
October 23, 2023

PharmaDrug consolidates shares, appoints new CFO

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF). said it will consolidate its common shares on a seven-to-one basis from October 24, 2023, and that the record

By Proactive Investors
September 14, 2023

PharmaDrug advances investigational cancer therapeutic PD-001 toward in human safety trials

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) said it continues to advance its patented reformulated enteric-coated version of orally bioavailable cepharanth

By Proactive Investors
September 6, 2023

PharmaDrug appoints Robert Steen as CEO and chairman

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced it has appointed seasoned entrepreneur Robert Steen as its new CEO and chairman of the Board of Direc

By Proactive Investors
July 18, 2023

PharmaDrug announces $300,000 strategic investment in Sairiyo subsidiary by PharmaTher

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) has announced a $300,000 investment in its Sairiyo Therapeutics biotech subsidiary by PharmaTher Inc, a wholly-

By Proactive Investors
May 23, 2023

PharmaDrug brings on veteran consultant to maximize cepharanthine and DMT program value

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced the addition of David Posner to its advisory committee and as a consultant with a mandate for strateg

By Proactive Investors
February 22, 2023

PharmaDrug partners with PharmaTher to develop DMT transdermal patch technology

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced that it has entered into a research collaboration agreement with PharmaTher Holdings Ltd to evaluate

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.